Aikido Pharma Inc
AIKI.OQ- Latest Trade
- trading higher5.89USD
- Change
- 0
- % Change
0.00%
- Day Range
- 5.62 - 5.97
- 52-Week Range
- 4.30 - 17.09
As of Jul 1 2022. Values delayed up to 15 minutes
- Previous Close
- 5.89
- Open
- 5.69
- Volume
- 11,109.00
- 3 Month Average Trading Volume
- 2.54
- Shares Out (Mil)
- 5.25
- Market Cap
- 30.99
- Forward P/E
- -1.65
- Dividend Yield
- -99,999.99
Key Statistics
2 mean rating - 1 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- -99,999.99
- Price To Book (Quarterly)
- 0.33
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 0.00
- Long Term Debt/Equity (Quarterly)
- 0.00
- Return On Investment (TTM)
- -6.09
- Return On Equity (TTM)
- -6.05
2021 (millions USD)
About Aikido Pharma Inc
Company Information
AIkido Pharma Inc. is a biotechnology company, with a diverse portfolio of small-molecule anticancer and antiviral therapeutics in development. The Company’s pipeline consists of patented technology from universities and researchers. The Company advances its therapeutic drug pipeline through a collaboration with educational institutions, including the University of Texas at Austin, the University of Maryland, Baltimore and Wake Forest University. Its oncology therapeutics include treatments for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is also developing a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. Its pancreatic drug candidate, DHA-dFdC, developed at and licensed from the University of Texas at Austin, is a chemotherapy treatment for advanced pancreatic cancer.
Address
ONE ROCKEFELLER PLAZA, 11TH FLOORNEW YORK, NY
10020
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Robert J. Vander Zanden
- Non-Executive Independent Chairman of the Board
- Anthony Hayes
- Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
- Soo Yu
- Director
- Gregory James Blattner
- Independent Director
- Robert Frederick Dudley
- Independent Director
- Tim S. Ledwick
- Independent Director
- Paul Lemire
- Independent Director
- Kyle Wool
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,804.90 | 0.04%Positive |
| Copper | 679.40 | 2.12%Negative |
| Brent Crude Oil | 111.90 | 2.63%Positive |
| CBOT Soybeans | 1,622.00 | 3.16%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,803.18 | 0.47%Positive |
| Euro STOXX 50 | 3,448.31 | 0.19%Negative |
| FTSE 100 | 7,168.65 | 0.01%Negative |
| Nikkei 225 | 25,935.62 | 1.73%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes